Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Letermovir

FDA-approved product (tablet, oral), marketed as Prevymis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Letermovir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cytomegalovirus infection
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antivirals
FDA pharmacologic class
Cytomegalovirus DNA Terminase Complex Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AX18

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Letermovir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Letermovir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

    NCT05763823 · start 2023-03-24

    Registered record
    Registry ID
    NCT05763823
    Conditions
    Cytomegalovirus Infection
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-03-24
    Completion
    2024-04-18
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infection
    InterventionLetermovir
    PhasePhase 3
    Registry statusCompleted

  • Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

    NCT05626530 · start 2023-02-02

    Registered record
    Registry ID
    NCT05626530
    Conditions
    Cytomegalovirus Infections; Infection in Solid Organ Transplant Recipients; Neutropenia; Antiviral Toxicity
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-02-02
    Completion
    2025-12-15
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections; Infection in Solid Organ Transplant Recipients; Neutropenia; Antiviral Toxicity
    InterventionLetermovir
    PhasePhase 4
    Registry statusRecruiting

  • HCMV Breakthrough Infections During Letermovir Prophylaxis

    NCT06339892 · start 2023-01-09

    Registered record
    Registry ID
    NCT06339892
    Conditions
    Cytomegalovirus Infections; Cytomegalovirus Viremia; Hematopoietic Stem Cell Transplantation
    Interventions
    Determination of HCMV DNA in plasma after DNAse digestion.; Determination of HCMV DNA in blood or plasma.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-01-09
    Completion
    2026-03
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections; Cytomegalovirus Viremia; Hematopoietic Stem Cell Transplantation
    InterventionDetermination of HCMV DNA in plasma after DNAse digestion.; Determination of HCMV DNA in blood or plasma.
    PhaseNot applicable
    Registry statusUnknown

  • Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies

    NCT05656599 · start 2023-01-03

    Registered record
    Registry ID
    NCT05656599
    Conditions
    CMV Infection; Hematopoietic Stem Cell Transplantation
    Interventions
    Letermovir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-01-03
    Completion
    2025-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV Infection; Hematopoietic Stem Cell Transplantation
    InterventionLetermovir
    PhaseNot recorded
    Registry statusUnknown

  • Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT

    NCT06306989 · start 2023-01-01

    Registered record
    Registry ID
    NCT06306989
    Conditions
    Letemovir for the Prevention of CMV Infection After Allo-HSCT
    Interventions
    Letermovir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-01-01
    Completion
    2025-12-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLetemovir for the Prevention of CMV Infection After Allo-HSCT
    InterventionLetermovir
    PhaseNot recorded
    Registry statusUnknown

  • Letermovir in ART-treated HIV-infected Persons

    NCT05362916 · start 2022-09-26

    Registered record
    Registry ID
    NCT05362916
    Conditions
    People Living With HIV
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-09-26
    Completion
    2025-01-27
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeople Living With HIV
    InterventionLetermovir
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

    NCT04840199 · start 2022-04-19

    Registered record
    Registry ID
    NCT04840199
    Conditions
    HIV Infections; Cytomegalovirus; CMV
    Interventions
    Letermovir Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-04-19
    Completion
    2023-11-30
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Cytomegalovirus; CMV
    InterventionLetermovir Oral Tablet
    PhasePhase 2
    Registry statusTerminated

  • Letermovir Use in Heart Transplant Recipients

    NCT04904614 · start 2022-01-05

    Registered record
    Registry ID
    NCT04904614
    Conditions
    Cytomegalovirus Disease; Cytomegalovirus Infections; Heart Transplant Infection; Antiviral Toxicity; Neutropenia
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-01-05
    Completion
    2025-01-14
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Disease; Cytomegalovirus Infections; Heart Transplant Infection; Antiviral Toxicity +1 more
    InterventionLetermovir
    PhasePhase 4
    Registry statusCompleted

  • Letermovir for CMV Prevention After Lung Transplantation

    NCT05041426 · start 2021-12-06

    Registered record
    Registry ID
    NCT05041426
    Conditions
    Lung Transplant; CMV
    Interventions
    Letermovir; Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-12-06
    Completion
    2025-03-03
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Transplant; CMV
    InterventionLetermovir; Valganciclovir
    PhasePhase 2
    Registry statusCompleted

  • Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1

    NCT04732260 · start 2021-06-11

    Registered record
    Registry ID
    NCT04732260
    Conditions
    Pregnant Women Undergoing TOP; TOP - Failed Attempted Termination of Pregnancy
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-06-11
    Completion
    2021-11-12
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnant Women Undergoing TOP; TOP - Failed Attempted Termination of Pregnancy
    InterventionLetermovir
    PhaseNot applicable
    Registry statusCompleted

  • Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

    NCT04312841 · start 2020-09-15

    Registered record
    Registry ID
    NCT04312841
    Conditions
    B-Cell Prolymphocytic Leukemia; Chronic Lymphocytic Leukemia; Peripheral T-Cell Lymphoma; Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; T-Cell Prolymphocytic Leukemia
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-09-15
    Completion
    2024-04-09
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-Cell Prolymphocytic Leukemia; Chronic Lymphocytic Leukemia; Peripheral T-Cell Lymphoma; Primary Cutaneous T-Cell Non-Hodgkin Lymphoma +2 more
    InterventionLetermovir
    PhasePhase 2
    Registry statusCompleted

  • MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

    NCT04129398 · start 2019-12-27

    Registered record
    Registry ID
    NCT04129398
    Conditions
    Cytomegalovirus Infection; Cytomegalovirus Disease
    Interventions
    Letermovir tablet; Letermovir IV
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-12-27
    Completion
    2022-10-06
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infection; Cytomegalovirus Disease
    InterventionLetermovir tablet; Letermovir IV
    PhasePhase 3
    Registry statusCompleted

  • Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

    NCT04060277 · start 2019-11-27

    Registered record
    Registry ID
    NCT04060277
    Conditions
    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid Cell Neoplasm; Hodgkin Lymphoma; Lymphoblastic Lymphoma; Myelodysplastic Syndrome; Myelofibrosis; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma
    Interventions
    Letermovir; Multi-peptide CMV-Modified Vaccinia Ankara Vaccine; Placebo Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-11-27
    Completion
    2030-04-07
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia +8 more
    InterventionLetermovir; Multi-peptide CMV-Modified Vaccinia Ankara Vaccine; Placebo Administration
    PhasePhase 2
    Registry statusActive not recruiting

  • Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

    NCT03940586 · start 2019-08-08

    Registered record
    Registry ID
    NCT03940586
    Conditions
    Cytomegalovirus (CMV) Infection
    Interventions
    Letermovir oral granules; Letermovir tablet; Letermovir intravenous
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-08-08
    Completion
    2023-08-25
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus (CMV) Infection
    InterventionLetermovir oral granules; Letermovir tablet; Letermovir intravenous
    PhasePhase 2
    Registry statusCompleted

  • A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

    NCT04017962 · start 2019-07-19

    Registered record
    Registry ID
    NCT04017962
    Conditions
    CMV; CMV Infection; Hematopoietic Cell Transplant
    Interventions
    Letermovir Pill; blood draw
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-19
    Completion
    2025-07-29
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV; CMV Infection; Hematopoietic Cell Transplant
    InterventionLetermovir Pill; blood draw
    PhasePhase 2
    Registry statusCompleted